-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Lymphoid Malignancies Sessions

Friday, December 6, 2024

top

7:00 AM-10:00 AM


Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia – What Clinicians Want to Know  
Friday Satellite Symposia


An Interactive Case-based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates  
Friday Satellite Symposia

11:00 AM-2:00 PM


Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma - What Clinicians Want to Know  
Friday Satellite Symposia


A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-free Treatment Paradigm  
Friday Satellite Symposia


Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors  
Friday Satellite Symposia


Crafting Custom Care in CLL: Guidance on Upfront and Sequential Treatment Decisions With Targeted and Immune-based Platforms  
Friday Satellite Symposia


Guiding Our Patient's Path: Managing First Relapse in Diffuse Large B-Cell Lymphoma Outside of CAR Ts  
Friday Satellite Symposia

1:30 PM-3:50 PM

ASH-a-Palooza


Blood Buddies: Adult Clinical Malignant Hematology
Trainee Activities and Services

2:03 PM-2:44 PM

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies


Epigenetic And Chromatin Mechanisms
Scientific Workshops

3:00 PM-6:00 PM


Bispecific Antibodies: A Playbook for Relapsed/Refractory Follicular Lymphoma  
Friday Satellite Symposia


Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios  
Friday Satellite Symposia

7:00 PM-10:00 PM


How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma  
Friday Satellite Symposia


Show Me the Data™: Pushing CAR T’s Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead  
Friday Satellite Symposia

Saturday, December 7, 2024

top

9:00 AM-7:30 PM


Poster Session I - Viewing  
Events

9:30 AM-10:45 AM


A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma  
Education Program


ALPS, CVID, and LGL: When Autoimmune Cytopenias Are a Marker of Underlying Immune Disease  
Education Program


Moving the Needle in Hodgkin Lymphoma  
Education Program


Not All Lymphadenopathy is Lymphoma: Lymphoproliferative Diseases of Immune Dysregulation  
Education Program


Proteo-Genomics to Better Study Multiple Myeloma Biology and Evolution  
Scientific Program

9:30 AM-11:00 AM


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Molecular Insights into Lymphomas and CLL  
Oral and Poster Abstracts


628. Aggressive Lymphomas: Cellular Therapies: Novel Strategies for Cell Therapies in Aggressive Lymphomas  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemia: Basic and Translational: Therapeutic Vulnerabilities, Signaling, and Microenvironment  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Decluttering Responses and Dynamic Risk: How Can We Improve Prognostication in Multiple Myeloma?  
Oral and Poster Abstracts


703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Novel Cell Platforms and Delivery Strategies  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: 'In with the Old, In with the New': Outcomes of Conventional and Novel Therapeutic Paradigms in Aggressive Lymphoid Malignancies  
Oral and Poster Abstracts

11:15 AM-12:15 PM


Career Development Lunch
Trainee Activities and Services

11:30 AM-12:30 PM


CAR T Cell Therapy for Second-line (2L) LBCL  
Product Theaters


Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.  
Product Theaters


Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL  
Product Theaters

12:00 PM-1:30 PM


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease  
Oral and Poster Abstracts


711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Innovations in Mobilization, Collection, and Manufacturing for Cellular Therapies  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies  
Oral and Poster Abstracts

1:30 PM-1:45 PM


Invivoscribe: Partnering with Pharma to Streamline Oncological Clinical Development  
Company Showcases

2:00 PM-3:15 PM


Host Factors Driving Anti-Leukemia Immunotherapy Outcomes  
Scientific Program


Newly Diagnosed Multiple Myeloma: Many Choices and More Questions  
Education Program

2:00 PM-3:30 PM


603. Lymphoid Oncogenesis: Basic: Molecular Insights into Acute Lymphoblastic Leukemias  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Targets in Aggressive Lymphomas  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Therapies for Mantle Cell Lymphoma  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomic and Epigenomic Insights into Myeloma Outcomes  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Addressing Hematologic and Immune Toxicities and the Status of Quad Therapies  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Quality Matters and Key Outcomes in Multiple Myeloma  
Oral and Poster Abstracts


Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities  
Special-Interest Sessions

3:30 PM-3:45 PM


The ALPHA3 Trial: Harnessing the Potential of Combining Next-Generation "Off-the-Shelf" Investigational CAR T Product with Advanced MRD Testing to Improve Outcomes in First Line LBCL  
Clinical Trial Showcases

4:00 PM-5:30 PM


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Determinants of Outcomes In ALL  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms  
Oral and Poster Abstracts


618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: Novel Immune Evasion Strategies in B Cell Lymphomas  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Novel Treatment Strategies and New Data on Old Standards for Follicular Lymphoma  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Advancing Minimal Residual Disease (MRD): Detection, Impact on Prognosis and Treatment Decisions  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients  
Oral and Poster Abstracts


902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Brighter Tomorrow - Improving Safety of Treatments  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations  
Oral and Poster Abstracts


ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation  
Special-Interest Sessions

4:00 PM-5:35 PM


JOINT SESSION: Molecular Characterization of Lymphomas in Children, Adolescents, and Young Adults  
Scientific Program

5:30 PM-7:30 PM


Poster Session I - Presentations (for in-person participants)  
Events


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Poster I  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Poster I  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster I  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster I  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I  
Oral and Poster Abstracts


618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Poster I  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: Poster I  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I  
Oral and Poster Abstracts


628. Aggressive Lymphomas: Cellular Therapies: Poster I  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster I  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I  
Oral and Poster Abstracts


652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Poster I  
Oral and Poster Abstracts


655. Multiple Myeloma: Cellular Therapies: Poster I  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster I  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Poster I  
Oral and Poster Abstracts


703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I  
Oral and Poster Abstracts


711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I  
Oral and Poster Abstracts


801. Gene Therapies: Poster I  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Poster I  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I  
Oral and Poster Abstracts


902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster I  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Poster I  
Oral and Poster Abstracts


908. Outcomes Research: Myeloid Malignancies: Poster I  
Oral and Poster Abstracts


909. Education, Communication, and Workforce: Poster I  
Oral and Poster Abstracts

Sunday, December 8, 2024

top

8:00 AM-9:00 AM


The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research  
Industry Theaters


Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL  
Product Theaters

9:00 AM-8:00 PM


Poster Session II - Viewing  
Events

9:30 AM-10:45 AM


Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.  
Scientific Program

9:30 AM-11:00 AM


615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Aggressive and T Cell Lymphomas  
Oral and Poster Abstracts


624. Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice-Changing Trials in Hodgkin Lymphoma  
Oral and Poster Abstracts


625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical Practice  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma  
Oral and Poster Abstracts


908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity  
Oral and Poster Abstracts


ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults  
Special-Interest Sessions

12:00 PM-1:30 PM


624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Mutations, Prognosis and MRD in CLL  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies  
Oral and Poster Abstracts

4:30 PM-5:45 PM


Biology Underlying Disparities in Lymphoid Malignancies  
Spotlight Sessions


Follicular Lymphoma: Playing the Long Game  
Education Program

4:30 PM-6:00 PM


614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Understanding and Exploiting Molecular Therapeutic Targets in ALL  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: Demystifying the Complexity of the Lymphoma Tumor Microenvironment and Immune Responses  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: New Prognostic Tools and Treatment Outcomes in Diffuse Large B Cell Lymphoma  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Microenvironment and Immunity in Myeloma  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Optimizing Therapy in Newly Diagnosed Myeloma and Beyond  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: B Cell-directed CAR T Cell Therapies for ALL and for Autoimmunity  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Frailty, Supportive Care, and Factors Impacting Outcomes  
Oral and Poster Abstracts

6:00 PM-8:00 PM


Poster Session II - Presentations (for in-person participants)  
Events


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Poster II  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster II  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Poster II  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: Poster II  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: Poster II  
Oral and Poster Abstracts


628. Aggressive Lymphomas: Cellular Therapies: Poster II  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster II  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II  
Oral and Poster Abstracts


652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Poster II  
Oral and Poster Abstracts


655. Multiple Myeloma: Cellular Therapies: Poster II  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster II  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Poster II  
Oral and Poster Abstracts


703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II  
Oral and Poster Abstracts


711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Poster II  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II  
Oral and Poster Abstracts


902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Poster II  
Oral and Poster Abstracts

Monday, December 9, 2024

top

7:30 AM-8:30 AM


ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by Blood Immunology & Cellular Therapy (For In-person Participants)  
ASH Poster Walks

9:00 AM-8:00 PM


Poster Session III - Viewing  
Events

10:30 AM-11:45 AM


A Shifting Landscape: Treatment of MCL  
Education Program


It's a Different World: CLL 2024  
Education Program


Smoldering Myeloma: A Case for Early Intervention?  
Spotlight Sessions

10:30 AM-12:00 PM


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Look into the Crystal B-ALL: Genetic, Phenotypic and Dynamic Outcome Predictors in Lymphoblastic Leukemia  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Single-cell and Spatial Analyses in Indolent Lymphomas  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Updates on Drug Treatments for Mantle Cell Lymphoma, and CAR-T and Transplants for Indolent Lymphomas  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemia: Basic and Translational: CLL and Richter Transformation: Functional Genomics and Molecular Mechanisms  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Uncovering New Targets and Disease Mechanisms in Myeloma  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant  
Oral and Poster Abstracts


902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials  
Oral and Poster Abstracts


903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes  
Oral and Poster Abstracts


ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies  
Special-Interest Sessions

2:45 PM-4:00 PM


Adult ALL Advancements: Optimizing Cure in 2024  
Education Program

2:45 PM-4:15 PM


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Mechanisms of Therapy Resistance in Lymphoma  
Oral and Poster Abstracts


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Treatment of BCR:ABL+ and T Cell Diseases  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Molecular Profiling and Prognostic Biomarkers in Hodgkin and Non-Hodgkin Lymphomas  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom's Macroglobulinemia and Hairy Cell Leukemia  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life  
Oral and Poster Abstracts


652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL Amyloidosis  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Acute and Late Toxicities Following CAR-T Cell Therapy  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies  
Oral and Poster Abstracts

4:30 PM-5:45 PM


Addressing Unmet Needs in T Cell Lymphomas  
Education Program

4:30 PM-6:00 PM


503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutic Approaches in Lymphoma  
Oral and Poster Abstracts


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: New Approaches and Models for Improving Lymphoma Therapies  
Oral and Poster Abstracts


625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas?  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: Chemotherapy-free Combinations for Relapsed Aggressive Lymphomas  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations  
Oral and Poster Abstracts


652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Into the Future: New Drugs and Combinations in Multiple Myeloma  
Oral and Poster Abstracts


655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Novel Targets and Therapeutic Approaches for CAR-T Cells  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs  
Oral and Poster Abstracts

6:00 PM-8:00 PM


Poster Session III - Presentations (for in-person participants)  
Events


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III  
Oral and Poster Abstracts


330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Poster III  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster III  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster III  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster III  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III  
Oral and Poster Abstracts


618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III  
Oral and Poster Abstracts


621. Lymphomas: Translational – Molecular and Genetic: Poster III  
Oral and Poster Abstracts


622. Lymphomas: Translational - Non-Genetic: Poster III  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Pharmacologic Therapies: Poster III  
Oral and Poster Abstracts


628. Aggressive Lymphomas: Cellular Therapies: Poster III  
Oral and Poster Abstracts


636. Myelodysplastic Syndromes: Basic and Translational: Poster III  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemia: Basic and Translational: Poster III  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III  
Oral and Poster Abstracts


652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


653. Multiple Myeloma: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


654. Multiple Myeloma: Pharmacologic Therapies: Poster III  
Oral and Poster Abstracts


655. Multiple Myeloma: Cellular Therapies: Poster III  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster III  
Oral and Poster Abstracts


702. CAR-T Cell Therapies: Basic and Translational: Poster III  
Oral and Poster Abstracts


703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III  
Oral and Poster Abstracts


711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III  
Oral and Poster Abstracts


803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III  
Oral and Poster Abstracts


902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster III  
Oral and Poster Abstracts


903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III  
Oral and Poster Abstracts


906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III  
Oral and Poster Abstracts


907. Outcomes Research: Plasma Cell Disorders: Poster III  
Oral and Poster Abstracts


908. Outcomes Research: Myeloid Malignancies: Poster III  
Oral and Poster Abstracts